Thermo Fisher Q2 revenue $11.99B (+10%), GAAP EPS $4.68 (+9%), adjusted EPS $6.03 (+13%)

THERMO FISHER SCIENTIFIC INC.

Organic revenue growth of 5%; GAAP operating margin 17.4% vs 16.9% YoY; adjusted operating margin 22.8% vs 21.9%.
Announced divestiture of microbiology business and repurchased $1.0B of stock during the quarter.
Launched new Orbitrap mass spectrometers with AI analytics and PowerFlex thermal cycler; opened U.S. Bioprocess Design Center.
Strategic collaboration with Precision Health Research, Singapore for PRECISE-SG100K population health study using Olink technology.
Company to provide updated 2026 financial guidance on earnings call at 8:30 a.m. ET.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.